MaxCyte, Inc. Clinical and Commercial License Agreement (2611H)
November 14 2018 - 2:00AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 2611H
MaxCyte, Inc.
14 November 2018
MaxCyte, Inc.
("MaxCyte")
Precision BioSciences and MaxCyte Enter into
Clinical and Commercial License Agreement
Precision BioSciences gains rights to MaxCyte's cell engineering
technology to develop next-generation, oncology-focused, cell
therapies with Precision's ARCUS(R) genome-editing technology
DURHAM, NC, and GAITHERSBURG, MD, 14 November 2018 - Precision
BioSciences (Precision) and MaxCyte (LSE: MXCT, MXCR) today
announced they have entered into a non-exclusive, clinical and
commercial license agreement that will allow Precision to use
MaxCyte's Flow Electroporation(R) technologies to robustly deliver
Precision's proprietary ARCUS genome-editing technology for use in
next-generation gene edited allogeneic T-cell immunotherapies
designed to treat a broad range of cancers.
David Thomson, Chief Development Officer of Precision, expressed
his support for the agreement, noting, "Precision's therapeutic
grade ARCUS editing platform is sufficiently compact and specific
to use with a range of delivery systems. In considering these, we
have found MaxCyte's electroporation technology complements our
approach to allogeneic T cell manufacturing, which is focused on
preserving cell quality throughout the process while maximizing
overall yield."
The clinical and commercial license builds upon an existing
research and clinical license agreement between Precision and
MaxCyte for the delivery of Precision's ARCUS technology into
T-cells. MaxCyte will supply its technology platform to Precision
as part of the license agreement and will receive future payments
including milestones and technology access licensing fees.
"The initiation of this commercial license agreement with
Precision, a leader in genome editing with its own proprietary
ARCUS technology, signifies a key milestone for MaxCyte and
demonstrates the value and versatility of our platform, our
intellectual property, and our ability to foster important
collaborations with companies generating life-changing gene
therapies," said Doug Doerfler, President & CEO of MaxCyte,
Inc.
MaxCyte's Flow Electroporation Technology enables the
engineering of a variety of therapeutically-relevant cell types at
high efficiency while maintaining high viability and recovery.
Precision's lead allogeneic CAR T programs rely on genome editing,
where ARCUS tools are used to transform healthy donor cells into
therapeutics using the MaxCyte technology. These cell therapies can
specifically target cancer cells in patients, potentially enabling
a unique and specialized approach to cancer treatment.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
About Precision BioSciences
Precision BioSciences is dedicated to improving life. Our
mission is to cure genetic disease, overcome cancer, and feed the
planet. We are striving to achieve this goal with ARCUS, our
therapeutic-grade, naturally-derived genome editing system that
combines both specificity and efficacy to help overcome life's
greatest genetic challenges. For additional information, please
visit www.precisionbiosciences.com.
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology platform
to help patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA therapies for its own
pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for
autologous cell therapy. In addition, through its core business,
the Company leverages its Flow Electroporation(R) Technology
platform to enable its biopharmaceutical industry partners to
advance the development of innovative, cutting-edge medicines,
particularly in cell therapy, including the use of gene editing
tools in the treatment of inherited genetic diseases and
immuno-oncology approaches to treating cancer. The Company has
placed its cutting-edge flow electroporation instruments worldwide,
with all of the top ten global biopharmaceutical companies, has
more than 55 partnered programme licenses in cell therapy including
more than 25 licensed for clinical use. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. For more information, visit
www.maxcyte.com
For more information, visit www.maxcyte.com.
PRECISION CONTACT:
Media:
Precision BioSciences +1 919 314 5512
Heather King, Director, Marketing Communications and PR
MAXCYTE CONTACTS:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon +44 (0)20 7886
Emma Earl 2500
Freddy Crossley
Corporate Broking
James Stearns
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709
Mary-Jane Elliott 5700
Chris Welsh maxcyte@consilium-comms.com
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRXXLLFVFFBFBZ
(END) Dow Jones Newswires
November 14, 2018 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024